The difference between patients with malignant leukemia is revealed by the observational genetics

S. and German scientists have identified three new subgroups of young granulocytes, single-nucleocytic leukemia (JMML), that can predict the "outcome" of the disease, including patients most likely to have the disease subside on its own, according to two independent cancer studies published in the British journal
on The 24th.
-monocyte leukemia is a malignant childhood cancer, which belongs to the abnormal disease of cloned hematopoietic stem cell hyperplising, mostly in in early childhood. To date, however, treatment for the disease has been limited. Current clinical and genetic markers do not explain the different clinical outcomes associated with the disease. Medical researchers believe dna methylation plays an important role in the disease, and two recent independent studies have shown that this overt genetic marker may help explain differences in outcomes in patients with different young granules-monocyte leukemia.
, scientists Christopher Pallas, Daniel Ripka and colleagues at the German Cancer Research Center analyzed DNA methylation patterns and mutations in 167 samples of early childhood granules-monocyte leukemia. They found three subgroups with different levels of methylation (high, medium, and low). In patients with high levels of methylation, poor clinical outcomes, patients with low levels of methylation had good prognostication, and mutations in all three groups were different, indicating an association between the activation of DNA methylation mechanisms and mutation patterns in patients with early-term granulocyte-monocyte leukemia.
in a separate study, a team at the University of California, San Francisco analyzed DNA methylation in 39 patients and identified three DNA methylation subgroups, where high methylation levels were associated with poor clinical outcomes and low methylation levels were associated with good prognosmation. The researchers verified this in 40 other patients.
new results provide the basis for dividing patients with different young granules-monocyte leukemia according to DNA methylation, and help to better understand the underlying biological mechanisms of the disease. (Source: Science and Technology Daily Zhang Mengran)